Revealing Genome-Wide Mrna and Microrna Expression Patterns in Leukemic Cells Highlighted “hsa-Mir as a Tumor Suppressor for Regain of Chemotherapeutic Imatinib Response Due To Targeting Stat5a
| dc.contributor.author | Tezcanlı Kaymaz, Burçin | |
| dc.contributor.author | Selvi Günel, Nur | |
| dc.contributor.author | Ceyhan, Metin | |
| dc.contributor.author | Bozok Çetintaş, Vildan | |
| dc.contributor.author | Özel, Buket | |
| dc.contributor.author | Kartal Yandım, Melis | |
| dc.contributor.author | Kıpçak, Sezgi | |
| dc.contributor.author | Aktan, Çağdaş | |
| dc.contributor.author | Adan Gökbulut, Aysun | |
| dc.contributor.author | Baran, Yusuf | |
| dc.contributor.author | Kosova Can, Buket | |
| dc.coverage.doi | 10.1007/s13277-015-3509-9 | |
| dc.date.accessioned | 2017-07-11T08:43:38Z | |
| dc.date.available | 2017-07-11T08:43:38Z | |
| dc.date.issued | 2015 | |
| dc.description.abstract | BCR-ABL oncoprotein stimulates cell proliferation and inhibits apoptosis in chronic myeloid leukemia (CML). For cure, imatinib is a widely used tyrosine kinase inhibitor, but developing chemotherapeutic resistance has to be overcome. In this study, we aimed to determine differing genome-wide microRNA (miRNA) and messenger RNA (mRNA) expression profiles in imatinib resistant (K562/IMA-3 μM) and parental cells by targeting STAT5A via small interfering RNA (siRNA) applications. After determining possible therapeutic miRNAs, we aimed to check their effects upon cell viability and proliferation, apoptosis, and find a possible miRNA | en_US |
| dc.description.sponsorship | Ege University Research Fund (APAK 2013-TIP/083) | en_US |
| dc.identifier.citation | Tezcanlı Kaymaz, B., Selvi Günel, N., Ceyhan, M., Bozok Çetintaş, V., Özel, B., Kartal Yandım, M., Kıpçak, S., Aktan, Ç., Adan Gökbulut, A., Baran, Y., and Kosova Can, B. (2015). Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted “hsa-miR-2278” as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A. Tumor Biology, 36(10), 7915-7927. doi:10.1007/s13277-015-3509-9 | en_US |
| dc.identifier.doi | 10.1007/s13277-015-3509-9 | en_US |
| dc.identifier.doi | 10.1007/s13277-015-3509-9 | |
| dc.identifier.issn | 1423-0380 | |
| dc.identifier.issn | 1010-4283 | |
| dc.identifier.scopus | 2-s2.0-84944280437 | |
| dc.identifier.uri | http://doi.org/10.1007/s13277-015-3509-9 | |
| dc.identifier.uri | https://hdl.handle.net/11147/5916 | |
| dc.language.iso | en | en_US |
| dc.publisher | SAGE Publications Inc. | en_US |
| dc.relation.ispartof | Tumor Biology | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | Apoptosis | en_US |
| dc.subject | Imatinib resistance | en_US |
| dc.subject | siRNA | en_US |
| dc.subject | STAT5A | en_US |
| dc.subject | Transcriptome and miRNome array | en_US |
| dc.subject | Chronic myeloid leukemia | en_US |
| dc.subject | MicroRNAs | en_US |
| dc.title | Revealing Genome-Wide Mrna and Microrna Expression Patterns in Leukemic Cells Highlighted “hsa-Mir as a Tumor Suppressor for Regain of Chemotherapeutic Imatinib Response Due To Targeting Stat5a | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| gdc.author.institutional | Kartal Yandım, Melis | |
| gdc.author.institutional | Adan Gökbulut, Aysun | |
| gdc.author.institutional | Baran, Yusuf | |
| gdc.author.yokid | 119193 | |
| gdc.bip.impulseclass | C4 | |
| gdc.bip.influenceclass | C5 | |
| gdc.bip.popularityclass | C4 | |
| gdc.coar.access | open access | |
| gdc.coar.type | text::journal::journal article | |
| gdc.collaboration.industrial | false | |
| gdc.description.department | İzmir Institute of Technology. Molecular Biology and Genetics | en_US |
| gdc.description.endpage | 7927 | en_US |
| gdc.description.issue | 10 | en_US |
| gdc.description.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | Q3 | |
| gdc.description.startpage | 7915 | en_US |
| gdc.description.volume | 36 | en_US |
| gdc.identifier.openalex | W271935301 | |
| gdc.identifier.pmid | 25953263 | |
| gdc.identifier.wos | WOS:000362969900065 | |
| gdc.index.type | WoS | |
| gdc.index.type | Scopus | |
| gdc.index.type | PubMed | |
| gdc.oaire.accesstype | GOLD | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.downloads | 67 | |
| gdc.oaire.impulse | 8.0 | |
| gdc.oaire.influence | 3.5368342E-9 | |
| gdc.oaire.isgreen | true | |
| gdc.oaire.keywords | Blotting, Western | |
| gdc.oaire.keywords | Apoptosis | |
| gdc.oaire.keywords | Real-Time Polymerase Chain Reaction | |
| gdc.oaire.keywords | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | |
| gdc.oaire.keywords | Biomarkers, Tumor | |
| gdc.oaire.keywords | STAT5 Transcription Factor | |
| gdc.oaire.keywords | Tumor Cells, Cultured | |
| gdc.oaire.keywords | Humans | |
| gdc.oaire.keywords | RNA, Messenger | |
| gdc.oaire.keywords | Imatinib resistance | |
| gdc.oaire.keywords | RNA, Small Interfering | |
| gdc.oaire.keywords | Protein Kinase Inhibitors | |
| gdc.oaire.keywords | Cell Proliferation | |
| gdc.oaire.keywords | Oligonucleotide Array Sequence Analysis | |
| gdc.oaire.keywords | Gene Expression Regulation, Leukemic | |
| gdc.oaire.keywords | Genome, Human | |
| gdc.oaire.keywords | Reverse Transcriptase Polymerase Chain Reaction | |
| gdc.oaire.keywords | Gene Expression Profiling | |
| gdc.oaire.keywords | Chronic myeloid leukemia | |
| gdc.oaire.keywords | Transcriptome and miRNome array | |
| gdc.oaire.keywords | STAT5A | |
| gdc.oaire.keywords | MicroRNAs | |
| gdc.oaire.keywords | Drug Resistance, Neoplasm | |
| gdc.oaire.keywords | siRNA | |
| gdc.oaire.keywords | Imatinib Mesylate | |
| gdc.oaire.popularity | 1.2124604E-8 | |
| gdc.oaire.publicfunded | false | |
| gdc.oaire.sciencefields | 0301 basic medicine | |
| gdc.oaire.sciencefields | 03 medical and health sciences | |
| gdc.oaire.sciencefields | 0303 health sciences | |
| gdc.oaire.views | 126 | |
| gdc.openalex.collaboration | National | |
| gdc.openalex.fwci | 1.90130035 | |
| gdc.openalex.normalizedpercentile | 0.84 | |
| gdc.openalex.toppercent | TOP 1% | |
| gdc.opencitations.count | 24 | |
| gdc.plumx.crossrefcites | 12 | |
| gdc.plumx.mendeley | 20 | |
| gdc.plumx.pubmedcites | 15 | |
| gdc.plumx.scopuscites | 29 | |
| gdc.scopus.citedcount | 29 | |
| gdc.wos.citedcount | 28 | |
| relation.isAuthorOfPublication.latestForDiscovery | 7bb863bb-9384-4a07-9fbb-b9c1ab7634a3 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | 9af2b05f-28ac-4013-8abe-a4dfe192da5e |